Table III.
Top-ranked canonical signalling pathways for saline (SAL), D-UFCB, D-SWCNT, D-MWCNT and ASB-exposed SAECs compared to dispersant-only exposed cells.
| Ingenuity canonical pathways | −log(p-value) | Ratio (%) |
|---|---|---|
| SAL | ||
| Hepatic fibrosis/hepatic stellate cell activation | 6.46 | 15.0 |
| Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis | 5.37 | 9.9 |
| IL-6 signalling | 4.07 | 14.0 |
| Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis | 3.63 | 9.6 |
| Renin–angiotensin signalling | 3.61 | 12.1 |
| GNRH signalling | 3.60 | 11.0 |
| Xenobiotic metabolism signalling | 2.96 | 8.6 |
| Atherosclerosis signalling | 2.95 | 11.2 |
| CD27 signalling in lymphocytes | 2.70 | 14.0 |
| LPS/IL-1-mediated inhibition of RXR function | 2.68 | 8.7 |
| D-UFCB | ||
| Hepatic fibrosis/hepatic stellate cell activation | 2.74 | 11.6 |
| Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F | 2.63 | 27.8 |
| Mitotic roles of polo-like kinase | 2.23 | 14.1 |
| Wnt/β-catenin signalling | 2.20 | 10.3 |
| Basal cell carcinoma signalling | 1.81 | 12.3 |
| Factors promoting cardiogenesis in vertebrates | 1.64 | 10.5 |
| D-SWCNT | ||
| TNFR1/TNFR2 signalling | 5.76 | 26.4 |
| CD27 signaling in lymphocytes | 4.01 | 21.1 |
| Death receptor signalling | 3.98 | 20 |
| Chronic myeloid leukaemia signalling | 3.86 | 16.2 |
| LPS-stimulated MAPK signalling | 3.56 | 17.1 |
| 14-3-3-mediated signalling | 3.55 | 15.8 |
| Angiopoietin signalling | 3.39 | 17.6 |
| Myc-mediated apoptosis signalling | 3.37 | 19.7 |
| 4-1BB signalling in T lymphocytes | 3.34 | 23.5 |
| Apoptosis signalling | 3.14 | 15.6 |
| D-MWCNT | ||
| Complement system | 3.24 | 20 |
| Role of IL-17A in arthritis | 3.17 | 14.3 |
| TNFR1 signalling | 2.98 | 15.1 |
| Aminosugars metabolism | 2.76 | 9.17 |
| Type II diabetes mellitus signalling | 2.61 | 8.75 |
| Atherosclerosis signalling | 2.57 | 10.3 |
| LXR/RXR activation | 2.55 | 10.8 |
| PTEN signalling | 2.5 | 9.68 |
| TWEAK signalling | 2.48 | 15.4 |
| LPS/IL-1-mediated inhibition of RXR function | 2.48 | 8.22 |
| ASB | ||
| Hepatic fibrosis/stellate cell activation | 8.08 | 13.6 |
| TREM1 signalling | 5.30 | 15.2 |
| Clathrin-mediated endocytosis signalling | 4.25 | 8.7 |
| Complement system | 4.23 | 20.0 |
| CTLA4 signalling in cytotoxic T lymphocytes | 3.99 | 11.2 |
| Leukocyte extravasation signalling | 3.97 | 8.50 |
| Virus entry via endocytic pathways | 3.82 | 11.0 |
| NF-κB signalling | 3.74 | 8.52 |
| Axonal guidance signalling | 3.68 | 6.0 |
| MSP-RON signalling pathway | 3.31 | 13.7 |